Optimizing Control Arms in Chronic Lymphocytic Leukemia Clinical Trials: The BRUIN-CLL-321 Trial.

Cliff ERS; Lew TE; Simon F; Hilal T; Anderson MA; Thompson PA; Seymour JF

doi:10.1200/JCO-25-01695

← 뒤로

Optimizing Control Arms in Chronic Lymphocytic Leukemia Clinical Trials: The BRUIN-CLL-321 Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2026 Vol.44(3) p. 254-256

Cliff ERS, Lew TE, Simon F, Hilal T, Anderson MA, Thompson PA, Seymour JF

원문 ↗ DOI ↗ BibTeX ↓ RIS ↓

이 논문을 인용하기

BibTeX ↓ RIS ↓

APA Cliff ERS, Lew TE, et al. (2026). Optimizing Control Arms in Chronic Lymphocytic Leukemia Clinical Trials: The BRUIN-CLL-321 Trial.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 44(3), 254-256. https://doi.org/10.1200/JCO-25-01695

MLA Cliff ERS, et al.. "Optimizing Control Arms in Chronic Lymphocytic Leukemia Clinical Trials: The BRUIN-CLL-321 Trial.." Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 44, no. 3, 2026, pp. 254-256.

PMID 41270246

DOI 10.1200/JCO-25-01695

같은 제1저자의 인용 많은 논문 (2)

Choosing between Nivo-AVD and BrECADD: Hodgkin lymphoma's new era.
British journal of haematology 2026
Cell-of-Origin Subtype Predicts Response to Polatuzumab Vedotin in Large B-cell Lymphoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2026